Leukemia Edition: Top Headlines for Week of March 13, 2023

In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more. Read the full coverage here:

Outpatient HSCT feasible for older adults with AML, myelodysplastic syndrome

Ponatinib ‘should be considered a standard of care’ for newly diagnosed Ph+ALL

Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML

Living along US-Mexico border linked to higher risk for death among children with leukemia

Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup

References:

Castellanos MI, et al. Cancer. 2023;doi:10.1002/cncr.34636.

Gyurkocza B, et al. Abstract LBA3. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.

Jabbour E, et al. Abstract 398868. Presented at: ASCO Plenary Series: February 2023 Session; Feb. 15, 2023.

Muffly L, et al. Abstract 86. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.

Press Release